Issue 52 of Lymphoma and Leukaemia Research Review

This issue begins with research reporting good tolerability of BR (bendamustine, rituximab) in patients aged ≥80 years with CLL, with efficacy and safety similar to that seen in younger patients as long as carefully adapted dosing is applied.

The PDF can be viewed here, and now you can also view the issue online.